Venture Summit West February 12 th, 2014 Silicon Valley
Slide 3
Slide 4
Computer Graphics Generated Image NOT ACTUAL Based on Codman
Device
Slide 5
Slide 6
Slide 7
SUPER BRIEF HISTORY Leonhardt Ventures founded in 1982. Has
since raised $145 million that has been invested in the development
of over 28 innovations and companies. 21 direct Leonhardt patents
and over 70 acquired or licensed patents or technologies. 1982-1985
Built dozens of cardiac cath labs & ICUs around the world.
1986-1994 Developed world leadership in polyurethane balloon
cardiovascular catheters. 1995-1998 Developed world leadership in
stent grafts and percutaneous heart valves. 1999 2008 Developed
world clinical leadership in stem cell repair of damaged heart
muscle. 2009 Launched Leonhardts Launchpads Life Science Incubator.
2008 to 2012 Developed world leadership in the development of
electrical stimulation for stem cell therapies. 2012 Launched Cal-X
Stars Innovation & Business Accelerator.
Slide 8
SUPER BRIEF HISTORY Major Exits Leonhardt Ventures and Core
Manufacturing Team Pacesetter Systems $1 billion > Siemans/St.
Jude AVE $4.3 billion > Medtronic (via WorldMed merger) Minimed
$4.3 billion > Medtronic Advanced Bionics $800 million >
Medtronic World Medical Mfg. Corp. $70 million > AVE Bioheart
$60 million > IPO 2008 (stock price down since) Note We in no
way attempt to claim full credit.
Slide 9
Market = 50 million+ people in heart failure. $40 billion +
Magnitude Problem = 25 million about to die in next 5 years with
current therapies. Current Pain = No other therapy regenerates scar
tissue back to muscle.`
Cost to Produce = $3000 Sell price = $29,000 Gross Profit =
$26,000 per unit Reimbursement = $58,000 for procedure = to CRT
Pacer, less than LVADs Total Annual Sales = $9 billion
Slide 12
Proven Team The Leonhardt and Core Manufacturing teams have had
more than $15 billion in exits in this space already. Track Record
= Pacemakers, Insulin Pump, Cardio Catheters, Stent Graft,
Intravascular Lung Catheter, Pain Pump, Percuntaneous Heart Valve,
Heart Pumps, Stem Cell Therapies, Stem Cell Recruiting Heart Pacer,
Biological Pacers, Wireless sensors.
Slide 13
MYOBLAST ENGRAFTMENT POST- TRANSPLANTATION Contractile muscle
tissue growing in the scarred portion of the heart following
treatment with myoblast injections. Human Heart, Proof of Concept *
Hagege et al., Viability and Differentiation of Autologous Skeletal
Myoblast Grafts in Ischemic Cardiomyopathy, Lancet, Vol. 361, 2003:
491-492
Slide 14
Scar tissue following heart attack Injection of skeletal
myoblasts into scar tissue using deflecting-tip catheter Cell
manufacturing following thigh muscle biopsy 1 3 2
Slide 15
Slide 16
p=0.50 MARVEL Phase II/III Randomized, Double Blinded, Placebo
Controlled American Heart Journal November 2011 Mean Change in
6-Minute Walk Distance (meters) n=6n=7n=6
Slide 17
BIO-LEONHARDT TEAMED WITH CORE MANUFACTURING
Slide 18
LEONHARDT VINEYARDS ESTABLISHED JANUARY 2000
Slide 19
Slide 20
BIO-LEONHARDT METHOD Pre-Treat Scar 1. Micro-RNAs (helps
converts scar to muscle). 2. Nutrient hydrogel 3. Electrical
stimulation via MyoStim Pacers of San Diego, California (produced
at Core Manufacturing in Los Angeles). 4. Growth factor infusion
ie; VEGF, SDF-1, HGF 5. Granulocyte colony stimulating factor. 6.
Endothelial progenitor cells derived from adipose tissue. Treat
Scar 1. TANAKA cardiac progenitor cells derived from skeletal
muscle as developed in Japan 2. Cardiac stem cells delivered at rim
edge of scar. 3. SDF-1 via Ono Pharmaceuticals in Japan. 4.
Nutrient hydrogel 5. Electrical stimulation from MyoStim Pacers San
Diego. 6. Injection of iPS cells with MicroRNAs. 7. Cardiobridge or
Procyrion implantable pump to allow heart to rest during healing
process. Post Treat Scar 1. Repeat injections of all of the above.
2. Continued electrical stimulation. 3. Continued delivery of
nutrient hydrogel and growth factors.
Slide 21
Slide 22
Slide 23
Slide 24
Slide 25
(1) The Kanno program stimulates angiogenesis (new blood vessel
growth). (2) The Chachques-Leonhardt program recruits stem cells to
injured heart tissue areas and proliferates them (includes resident
cardiomyocytes). (3) The Leonhardt-Chachques program differentiates
recruited and/or injected stem cells to beating heart muscle. (4)
The Leonhardt program senses arrhythmia's-fibrillation and delivers
a low voltage pulse to restart a patient's heart back to a normal
beat. (5) The final program is a standard synchronization-pacing
program.
Slide 26
STIMULATION OF ANGIOGENESIS Capillary density in rat TA
muscles. Number of capillaries was counted in at least 8 different
fields, and capillary density was obtained by calculation of
capillary/muscle fiber area.
Slide 27
Slide 28
Slide 29
Slide 30
Investment Opportunity Valuation = $5 million Raising Seed
Round = $1 million New investors = 20% Ownership Amount Invested to
Date = *$450,000 Current Investors = Leonhardt Ventures, Airspeed
Equity, Core Manufacturing LLC
Slide 31
LEONHARDT VENTURES WORLDS FIRST STEM CELL RECRUITING BRA
Slide 32
LEOHARDT VENTURES FOUNDED THE FIRST CONSCIOUS CAPITALISM STOCK
EXCHANGE